HOME >> MEDICINE >> NEWS
Drug Combination Including New "Super Aspirin" Drug Cuts Risk Of Death Or Second,,Heart Attack

DALLAS, June 23 -- In a growing class of blood-thinning drugs to treat heart attack, researchers have found one that seems to have a greater long-term benefit rather than only an immediate effect, according to a study released in today's Circulation: Journal of the American Heart Association.

The drug, lamifiban, is in a class of drugs called "platelet IIb/ IIIa receptor blockers," which prevent platelets from forming blood clots that obstruct blood vessels and cause heart attacks. Through a different mechanism, aspirin has a much weaker effect on platelets.

Lamifiban was used alone in varying doses and in combination with heparin, a blood-thinning agent.

The new drug combination may be used to treat patients who have severe chest pain or have had a non-Q-wave, or limited, heart attack. Standard in-hospital treatment for these individuals involves aspirin and heparin.

The study, co-authored by David J. Moliterno, M.D. is among several that are looking into ways to reduce heart attack survivors' high risk for death or a second heart attack in the first year following the attack, with the most critical period being in the first few weeks.

His study is unique in that it suggests a long-term benefit rather than an immediate effect alone. Even with standard treatment, "There is still room for improvement," says Moliterno, of the department of cardiology at The Cleveland Clinic Foundation, Cleveland, Ohio. The number of deaths and second heart attacks is high even at six months after the initial attack, he says.

The Circulation report, however, indicates that if heart attack patients survive the first 30 days, the chances of surviving past six months or even a year are better if they receive lamifiban compared with standard treatment.

"We don't know specifically how long before each individual patient is stabilized after a heart attack," says Moliterno. "Most deaths and second heart attacks tend to oc
'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-706-1279
American Heart Association
22-Jun-1998


Page: 1 2

Related medicine news :

1. Combination treatment helps thyroid cancer patients live longer
2. Combination therapy, not medication alone, most effective for treating children with OCD
3. Combination of erection pill and testosterone gel may benefit men who fail treatment with pill alone
4. Combination therapy w/ ACTOS (pioglitazone HCI) shown to improve components of diabetic dyslipidemia
5. Combination PET/CT should be used to determine stage of non-small cell lung cancer
6. Combination of toxin and poison may be novel treatment for leukemia
7. Combination drug therapy could substantially improve symptoms of rheumatoid arthritis
8. Combination therapy does not appear to benefit cardiac patients before heart catheter procedure
9. Combination drug therapy offers hope for malaria treatment
10. Combination therapy significantly delays progression of benign prostatic hyperplasia
11. Combination, order of anti-HIV drugs make a difference in first-time recipients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... 20, 2017 (PRWEB) , ... ... ... a global provider of enterprise-grade IT operations analytics and application performance monitoring ... one of world’s largest healthcare services providers. , According to Peter Ohrenberger, ...
(Date:7/20/2017)... ... ... Doctors on Liens, the leading network of medical providers working on a ... Russell Horine, DC to their exclusive list of medical professionals. Horine Chiropractic is a ... the clinic director and his son Dr. Lee Horine and daughter-in-law Dr. Natalie Horine ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced today ... existing adherence automation lines. The ATP® Mini and InspectRx® Mini are ... standard products, but at a size and price point that can help pharmacies ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... LINET, an ... latest innovation to their product line: the AVE 2 birthing bed. , Perfectly suitable ... bring a new level of comfort and efficiency to every phase of childbirth. The ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... million Health Resources and Services Administration (HRSA) grant to train predoctoral dental students ... care needs in rural and underserved areas. , The Predoctoral Pediatric Training Project ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017  The global market for ... of approximately $394.1 million in 2016.  Although in early ... solid growth, in particular as a result of the ... and the recent introduction of a significant number of ... less-invasive testing of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
Breaking Medicine Technology:
Cached News: